This is the first resource to provide researchers in academia and industry with an urgently needed update on drug intervention against trypanosomatides. As such, it covers every aspect of the topic from basic research findings, via current treatments to translational approaches in drug development and includes both human and livestock diseases. The outstanding editor and contributor team reads like a Who?s Who of the field, thus guaranteeing the outstanding quality of this ready reference.

Parasitic Skin Diseases: Advances in Research and Treatment: 2011 Edition is a ScholarlyPaper™ that delivers timely, authoritative, and intensively focused information about Parasitic Skin Diseases in a compact format. The editors have built Parasitic Skin Diseases: Advances in Research and Treatment: 2011 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Parasitic Skin Diseases in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Parasitic Skin Diseases: Advances in Research and Treatment: 2011 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.

Medicinal Chemistry of Neglected and Tropical Diseases: Advances in the Design and Synthesis of Antimicrobial Agents consolidates and describes modern drug discovery and development approaches currently employed to identify effective chemotherapeutic agents for the treatment of Neglected Tropical Diseases (NTDs) from a medicinal chemistry perspective. Chapters are designed to cater to the needs of medicinal chemists who work with chemotherapeutic developments for NTDs, as well as serve as a guide to budding medicinal chemists who wish to work in this area. It will introduce rational drug design approaches adopted in designing chemotherapeutics and validated targets available for the purpose.

The Microbiology of Central Nervous System Infections, Volume 3, discusses modern approaches to the diagnosis, treatment and prophylaxis of central nervous system (CNS) infections. This new release is divided into five sections that cover treatment strategies, imaging, molecular diagnosis, management of CNS infections with metal nanoparticles, and prophylaxis of CNS infections, including bacterial, viral and fungal infections. The last section contains a chapter on transmissible spongiform encephalopathies and modern trends in its diagnosis and treatment. University teachers, medical practitioners, graduate and postgraduate students, researchers in microbiology, and those in the pharmaceutical and laboratory diagnostic industries will find the book very important. - Encompasses a broad range of central nervous system infections, including questions of etiology, pathogenesis, diagnosis, prognosis, treatment and prophylaxis - Written by highly professional and eminent surgeons, microbiologists and infectious disease specialists - Includes scientific understanding and practical guidelines, making it interesting for both research scientists and practitioners

Issues in Medical Microbiology, Mycology, Virology, and Molecular Medicine: 2013 Edition is a ScholarlyEditions™ book that delivers timely, authoritative, and comprehensive information about Medical Microbiology. The editors have built Issues in Medical Microbiology, Mycology, Virology, and Molecular Medicine: 2013 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Medical Microbiology in this book to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Issues in Medical Microbiology, Mycology, Virology, and Molecular Medicine: 2013 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.

The Diagnosis and Treatment of Protozoan Diseases discusses about major protozoan diseases such as Malaria, Leishmaniasis, etc., including clinically minor protozoan diseases. This book provides all essential information to the professional researcher and medical personnel about the disease, causative organism, and their lifecycle, diagnostics, and treatments, including drugs and vaccine, resistance and key points of future research. Infectious diseases are accountable for millions of deaths every year throughout the globe. Among them, significant contributors are protozoan parasites. Despite the many research group working on the various protozoan diseases, there are still major gaps to fill.The authors of this book have critically reviewed all the aspects of major protozoan diseases, their diagnostics, and treatments including resistance. - Presents comprehensive coverage on all aspects of major protozoan diseases - Includes updates on their lifecycle, diagnostics, and treatment - Covers future research that may help eradicate these diseases

As it is a goal to eliminate human African trypanosomiasis (HAT; sleeping sickness) as a public health problem by 2020 and interrupt transmission by 2030, this is a good moment to reflect on what we have achieved, what we want to achieve, and what could get in our way. HAT has a reputation for spectacular reappearances, and the latest peak of 40,000 reported and over 300,000 estimated cases only dates back to 1998. Efforts of the WHO and partners as well as the development of simpler and much better-tolerated treatments, improved diagnostics, and vector control tools made it possible to reduce this number by 95%. Case identification and confirmation remain complex and require specific skills, treatment remains error-prone and reports on long-term survivors have emerged, and the relevance of the animal reservoir for T. b. gambiense HAT needs clarification. In addition, to win the “end game” against this massively stigmatized disease, the human factor will play a key role. This Special Issue addresses many of the burning topics about disease elimination in its 12 research and 7 review articles and one case study. The papers critically reflect the approaches used, investigate the mentioned challenges, and propose novel approaches and interventions from various points of view.

Some of the more recent efforts in tuberculosis (TB) and trypanosomiasis drug discovery from both Product Development Partnerships (PDPs) and academia are highlighted in this this volume. Drug discovery approaches include both target- and phenotypic whole cell screening- approaches. Regarding the latter, mechanism of action studies through target identification are also illustrated. Provides an overview of the status of some of the current novel compounds in development as well as new emerging treatment options targeting novel mechanisms of action Identification of hits from phenotypic whole cell screening, followed by target identification Strategies aimed at improving the efficacy of existing clinically used anti-TB drugs by taking advantage inhibitors of mycobacterial transcriptional regulators to boost the anti-tubercular activity, and circumvent acquired-resistance